Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209660 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
A Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 8
- Study locations
NCT04209660: Active Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04209660 is a Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 64 participants, below the 124-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (48% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04209660, a Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. Researchers are also doing this study to test the safety of the study drugs in participants.
Primary Outcome
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (8)
New York
- Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Florida
- Baptist Alliance MCI - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT04209660 still lists
NCT04209660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 124-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (48% lower).
The record links to 2 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04209660 lists 8 locations in 3 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT04209660 about?
NCT04209660 is a clinical study titled "Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers". The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. Researchers are also doing this study to test the safe...
What is the current status of trial NCT04209660?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2020-06-02. Estimated completion is 2026-12.
What conditions does trial NCT04209660 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Salivary Gland Cancer.
What interventions are being tested in trial NCT04209660?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04209660?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04209660 being conducted?
This trial has 8 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04209660's enrollment target sits among peer trials
64 7th of 16 higher than 10 of 16 other Adenoid Cystic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenoid Cystic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI